Belite Bio (BLTE) Income from Continuing Operations (2022 - 2026)

Belite Bio's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 26938000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 88.68% year-over-year to 26938000.0 in Q1 2026; TTM through Mar 2026 was 63360938000.0, a 124.04% decrease from a year earlier, with the FY2025 full-year figure at 77475000.0, down 131.85% from the prior year.
• Income from Continuing Operations grew to 26938000.0 in Q1 2026 per BLTE's latest filing, from 25324000000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 6783000.0 in Q4 2022 and bottomed at 25324000000.0 in Q4 2025.
• The 5-year median for Income from Continuing Operations is 6853500000.0 (2023), against an average of 7377433062.5.
• Across the five-year window, Income from Continuing Operations plunged 144392.13% in 2024 and soared 99.82% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 6783000.0 in 2022, then declined by 3.05% to 6990000.0 in 2023, then plunged by 144392.13% to 10100000000.0 in 2024, then tumbled by 150.73% to 25324000000.0 in 2025, then jumped by 99.89% to 26938000.0 in 2026.
• Per Business Quant, the three latest BLTE Income from Continuing Operations figures stand at 26938000.0 (Q1 2026), 25324000000.0 (Q4 2025), and 21690000000.0 (Q3 2025).